BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 38532833)

  • 1. Modulation of Epithelial-Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel.
    Nakamura H; Watanabe M; Takada K; Sato T; Hikage F; Umetsu A; Muramatsu J; Furuhashi M; Ohguro H
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38790973
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Ho TJ; Tsai BC; Debakshee G; Shibu MA; Kuo CH; Lin CH; Lin PY; Lin SZ; Kuo WW; Huang CY
    Heliyon; 2024 May; 10(9):e29729. PubMed ID: 38698985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells.
    Hour MJ; Tsai FJ; Lai IL; Tsao JW; Chiang JH; Chiu YJ; Lu HF; Juan YN; Yang JS; Tsai SC
    Biomedicine (Taipei); 2023; 13(4):20-31. PubMed ID: 38532833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic Anticancer Effects of Gemcitabine with Pitavastatin on Pancreatic Cancer Cell Line MIA PaCa-2 in vitro and in vivo.
    Chen YH; Chen YC; Lin CC; Hsieh YP; Hsu CS; Hsieh MC
    Cancer Manag Res; 2020; 12():4645-4665. PubMed ID: 32606957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heptadecanoic Acid, an Odd-Chain Fatty Acid, Induces Apoptosis and Enhances Gemcitabine Chemosensitivity in Pancreatic Cancer Cells.
    Kim HY; Moon JY; Cho SK
    J Med Food; 2023 Mar; 26(3):201-210. PubMed ID: 36716276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
    Duong HQ; Hwang JS; Kim HJ; Kang HJ; Seong YS; Bae I
    Int J Oncol; 2012 Sep; 41(3):855-61. PubMed ID: 22710732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
    Arnoletti JP; Buchsbaum DJ; Huang ZQ; Hawkins AE; Khazaeli MB; Kraus MH; Vickers SM
    J Gastrointest Surg; 2004 Dec; 8(8):960-9; discussion 969-70. PubMed ID: 15585383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis.
    Chiu HY; Tsai SC; Tsai FJ; Lo YH; Cheng CC; Liu TY; Jhan SR; Yang JS; Chiu YJ
    In Vivo; 2023; 37(3):1037-1046. PubMed ID: 37103096
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Cheng YD; Lu CC; Hsu YM; Tsai FJ; Bau DT; Tsai SC; Cheng CC; Lin JJ; Huang YY; Juan YN; Chiu YJ; Kuo SC; Yang JS; Wu LT
    Biomedicine (Taipei); 2022; 12(3):56-71. PubMed ID: 36381194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance.
    Capula M; PerĂ¡n M; Xu G; Donati V; Yee D; Gregori A; Assaraf YG; Giovannetti E; Deng D
    Drug Resist Updat; 2022 Sep; 64():100864. PubMed ID: 36115181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of gemcitabine-based combination therapy
    Zhang Z; He S; Wang P; Zhou Y
    J Gastrointest Oncol; 2022 Aug; 13(4):1967-1980. PubMed ID: 36092340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MTH-3 sensitizes oral cancer cells to cisplatin via regulating TFEB.
    Tsai SC; Yang JS; Lu CC; Tsai FJ; Chiu YJ; Kuo SC
    J Pharm Pharmacol; 2022 Sep; 74(9):1261-1273. PubMed ID: 35880728
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.